The next focusIR Investor Webinar takes places on 14th May with guest speakers from Blue Whale Growth Fund, Taseko Mines, Kavango Resources and CQS Natural Resources fund. Please register here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksMTFB.L Share News (MTFB)

  • There is currently no data for MTFB

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

UK EXECUTIVE CHANGE SUMMARY: Scapa Healthcare, Industrial Heads Resign

Mon, 04th May 2020 15:42

(Alliance News) - The following is a round-up of London-listed company director and manager changes announced on Monday and not separately reported by Alliance News:

----------

Scapa Group PLC - healthcare and industrial design - Hires John Petreanu as president of Healthcare, replacing Joe Doherty, from Monday. Petreanu most recently was vice president of operations for Viant Medical, a service provider to medical device makers, having previously been chief operating officer for Scapa Healthcare. Meanwhile, Scapa Chief Executive Heejae Chae will take on the additional role of president of Industrial, replacing Sevan Demirdogen. Both Doherty and Demirdogen resign "to pursue other business opportunities". Additionally, Chae volunteers for a 20% cut in basic salary during the Covid-19 crisis. Scapa expects to report underlying trading profit for the financial year that ended March 31 in line with the guidance it provided back in February.

----------

Attraqt Group PLC - online retail software - Hires Mark Adams as CEO, joining on June 22 from BigCommerce, an e-commerce platform provider. Current CEO Luke McKeever will move to non-executive director at that time and Nick Habgood will move back to non-executive chair from interim executive chair. Attraqt was named a BigCommerce Technology Partner back in February, and the two companies have a number of joint customers and pipeline prospects.

----------

Red Rock Resources PLC - gold, manganese and mineral development - Scott Kaintz moves from chief operating officer and chief financial officer to non-executive director, effective from Friday last week, due to becoming chief executive officer of Regency Mines PLC. Red Rock said Kaintz will remain in the non-executive role to provide a transition once a new CFO is found.

----------

Clipper Logistics PLC - e-fulfilment and returns management - Promotes COO Stefan Van-Hoof to deputy CEO, reporting to CEO Tony Mannix, effective immediately. Van-Hoof joined Clipper in 2016 and previously was managing director of its European business. Martin O'Grady is promoted to COO to replace Van-Hoof from senior operations director.

----------

Target Healthcare REIT PLC - investor in care homes - Alison Fyfe hired as independent non-executive director, effective from Friday last week. Fyfe worked for Royal Bank of Scotland Group PLC for 19 years, ending as head of real estate restructuring in Scotland in 2015.

----------

Motif Bio PLC - AIM cash shell - Graham Lumsden steps down as CEO to become non-executive director, while CFO Jonathan Gold adds the role of president & chief business officer. Bruce Williams remains chair, and Chris Wardhaugh is added as non-executive director. Wardhaugh is chief business officer of MGB Biopharma Ltd and is founder of Sercader Ltd, a life sciences advisory firm. Williams said Wardhaugh's transactional experience will be useful as Motif Bio looks for a reverse takeover candidate, which it must do by July 28 or have its shares suspended from trading on AIM. The company said it has GBP230,000, giving it a cash runway into June.

----------

Big Yellow Group PLC - storage space provider - Hires Laela Tabrizi as non-executive director from July 1. Tabrizi is CFO of MotorK, which provides digital solutions for automotive sales and marketing. Georgina Harvey to step down as non-executive director after seven years at upcoming annual general meeting, normally held in July. Last month Big Yellow raised GBP81.9 million in a share placing.

----------

Trident Resources PLC - mining royalty and streaming - Hires Al Gourley as non-executive director. Gourley is the London managing partner of law firm Fasken Martineau and has been director of several Toronto and London listed mining and mineral exploration companies.

----------

By Tom Waite; thomaslwaite@alliancenews.com

Copyright 2020 Alliance News Limited. All Rights Reserved.

More News
24 Oct 2019 10:31

UK WINNERS & LOSERS SUMMARY: Woodford Trust Up 30% As Schroders Tapped

UK WINNERS & LOSERS SUMMARY: Woodford Trust Up 30% As Schroders Tapped

Read more
10 Oct 2019 11:52

Motif Bio Meeting With US FDA Confirms Need For Another iclaprim Trial

Motif Bio Meeting With US FDA Confirms Need For Another iclaprim Trial

Read more
2 Oct 2019 11:59

Motif Bio To Raise GBP600,000 Via Placing To Fund Major Restructure

Motif Bio To Raise GBP600,000 Via Placing To Fund Major Restructure

Read more
1 Oct 2019 17:09

Motif Bio To Become Cash Shell If Restructuring Proposals Accepted

Motif Bio To Become Cash Shell If Restructuring Proposals Accepted

Read more
2 Sep 2019 11:39

Motif Bio Delays Next Amortisation Date Of Hercules Loan Facility

(Alliance News) - Novel antibiotics-focused biopharmaceutical company Motif Bio PLC said Monday it has agreed with Hercules Capital Inc to postpone the next amortisation date for its loan and date

Read more
19 Aug 2019 10:46

WINNERS & LOSERS SUMMARY: IXICO Rises On Positive Outlook

(Alliance News) - The following stocks are the leading risers and fallers within the main London indices on Monday.----------FTSE 100 - WINNERS----------J up 3.8%. The is

Read more
19 Aug 2019 09:29

Motif Bio Receives US State Funding For Iclaprim Listeria Study

(Alliance News) - Biopharmaceutical firm Motif Bio PLC said Monday that the US government will fund a study on the effectiveness of the iclaprim drug against listeria monocytogenes.Shares a

Read more
1 Aug 2019 11:43

Motif Bio Postpones Next Amortisation Date Of Hercules Loan Facility

(Alliance News) - Biopharmaceutical firm Motif Bio PLC said on Thursday has amended its loan agreement with Hercules Capital Inc, delaying the next amortisation date by one month to September a to

Read more
12 Jun 2019 18:16

Amphion Innovations To Work With Debt Providers To Refinance Facility

(Alliance News) - Amphion Innovations PLC said Wednesday its debt providers have told the company the excess value of the collateral does not meet the terms of an agreed facility between the in at

Read more
6 Jun 2019 10:47

WINNERS & LOSERS SUMMARY: Rolls Royce And L&G Rise On Pension Pact

LONDON (Alliance News) - The following stocks are the leading risers and fallers within the main London indices on Thursday.----------FTSE 100 - WINNERS----------Rolls up

Read more
31 May 2019 15:32

Motif Bio Shareholders Reject Remuneration Report Resolution

LONDON (Alliance News) - Motif Bio PLC on Friday said that shareholders voted against approval of the company's remuneration report.At the clinical-stage biopharmaceutical firm's on

Read more
1 May 2019 10:46

Motif Bio to work with Lamellar on cystic fibrosis treatment possibility

(Sharecast News) - Clinical-stage biopharmaceutical company Motif Bio has signed an agreement with Lamellar Biomedical, under which Motif Bio would conduct an in vivo preclinical study evaluating iclaprim in combination with Lamellar's patented 'Lamellasome' technology.

Read more
1 May 2019 09:26

Motif Bio Shares Up On Agreement With Lamellar To Start Clinical Study

LONDON (Alliance News) - Shares rose in Motif Bio PLC on Wednesday as it signed an agreement with Lamellar Biomedical to study the combination of Motif's iclaprim with Lamellar's in the at

Read more
26 Apr 2019 14:09

Motif Bio Appoints Andrew Powell As Non-Executive Director

LONDON (Alliance News) - Motif Bio PLC, a clinical-stage biopharmaceutical company specialising in developing novel antibiotics, said Friday it has appointed Andrew Powell as non-executive has as

Read more
15 Apr 2019 10:50

Motif Bio 2018 Loss Narrows As Research Costs Fall Despite US Delay

LONDON (Alliance News) - Motif Bio PLC said Monday its 2018 loss narrowed significantly as research costs fell, despite an unexpected delay in its new drug application in the US.In 2018, to

Read more

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.